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Purpose: The purpose of this study was to evaluate whether predicted tumor volume 
could predict pathologic stage in patients undergoing radical prostatectomy. 
Materials and Methods: The clinical and pathologic data of 236 patients who underwent 
a 12-core needle biopsy followed by radical prostatectomy were obtained from our data-
base and reviewed retrospectively. 
Results: Observed tumor volume correlated best with serum prostate-specific antigen 
(PSA) level (r=0.677, p＜0.001) and the number of positive biopsy cores (r=0.489, p
＜0.001). Stepwise multiple linear regression analysis was used to develop a model for 
predicting tumor volume before radical prostatectomy. All explanatory variables ex-
cept PSA and the number of positive biopsy cores were eliminated, yielding the equation 
([predicted tumor volume]=0.381x[PSA]＋0.921x[No. of positive biopsy cores]−0.992). 
Tumor volume predicted by this equation correlated strongly with observed tumor vol-
ume (r=0.722, p＜0.001). This was also true when a different cohort of 159 patients was 
analyzed (r=0.638, p＜0.001). The areas under the receiver operating characteristic 
curves of predicted tumor volume were 68.5% for extracapsular extension, 75.7% for 
seminal vesicle invasion, and 70.4% for positive surgical margin. Kaplan-Meier curves 
revealed that predicted tumor volume correlated significantly with biochemical re-
currence-free survival (p＜0.001; log-rank test). 
Conclusions: Our findings suggest that tumor volume predicted on the basis of PSA 
levels and number of positive biopsy cores may predict pathologic stage with reasonable 
accuracy. 
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INTRODUCTION
It has been suggested previously that the malignant poten-
tial of prostate cancer correlates strongly with the size of 
the primary cancer [1]. Reflecting this, all definitions of 
clinically significant vs. potentially insignificant prostatic 
carcinoma incorporate tumor size measurements [2,3]. 
Numerous studies have also shown that prostate cancer 
volume correlates with other prognostic indicators and 
with progression after radical prostatectomy [4,5]. These 
observations suggest that obtaining an accurate estima-
tion of tumor volume preoperatively might aid the treat-
ment decision. However, it remains difficult to estimate tu-
mor volume preoperatively on the basis of clinical parame-
ters such as preoperative biopsy data. Indeed, there is often 
significant discord between the extent of cancer detected 
on biopsy and the tumor volume in the final surgical speci-
men [6,7]. Moreover, although prostate-specific antigen 
(PSA) is the most widely used tumor marker in clinical 
practice for the diagnosis, staging, and monitoring of pros-
tate cancer, PSA associates only weakly with prostate can-
cer volume in men treated by radical prostatectomy [8]. 
The aim of this study was to determine whether it is pos-
sible to estimate tumor volume on the basis of preoperative 
clinical variables and whether such predicted tumor vol-
umes could predict pathologic stage in patients who under-Korean J Urol 2011;52:24-30
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go radical prostatectomy. For this purpose, we developed 
a regression model composed of several preoperative varia-
bles to predict total tumor volume.  
MATERIALS AND METHODS
1. Patient population 
Approval of the study was obtained from the Institutional 
Review Board of our institution. Between 2000 and 2004, 
260 radical retropubic prostatectomies for the treatment 
of prostate cancer were performed at a single institution. 
The clinical and pathologic data of these patients were ob-
tained from our surgical database and were reviewed 
retrospectively. Patients with positive lymph nodes and 
who had received neoadjuvant or immediate adjuvant an-
drogen ablation or radiotherapy were excluded from the 
study. A total of 236 patients were included in the study. 
Individuals who visited our department for a variety of rea-
sons, such as prostate cancer screening or because of void-
ing symptoms, were enrolled regardless of whether the vis-
it was primary or referred. Patients with high serum PSA 
levels or abnormal digital rectal examination (DRE) find-
ings underwent a 12-core needle biopsy; all biopsies were 
performed by a single radiologist. The DRE was performed 
by senior urologists at our institution. The patients’ me-
dian age at the time of surgery was 67.2 years (range, 
41.8-80.7 years). The median preoperative PSA level was 
8.1 ng/ml (range, 0.7-98.0 ng/ml). None of the patients had 
evidence of nodal disease or distant metastasis on either 
contrast-enhanced computed tomography or bone scans. 
2. Histologic analysis 
The presence of carcinoma in needle biopsy tissue was as-
sessed by a single pathologist (K.C.M). Gleason primary 
and secondary grades with sum scores were assigned, and 
the number of core biopsy specimens that contained carci-
noma was quantified. The radical prostatectomy speci-
mens were handled and processed in a standard manner, 
in which all prostatic tissue was embedded as previously 
described [9]. The total tumor volume and the tumor vol-
ume of each cancer focus were calculated by using the for-
mula 0.4 x length x width x cross-sectional thickness, i.e., 
number of cross sections x section thickness [10]. All speci-
mens were scored according to the Gleason grading system. 
The pathologic stages were determined on the basis of the 
2002 TNM classification, and a positive surgical margin 
was defined as the presence of cancer cells in the inked sur-
face of the prostate specimen. 
3. Follow-up
Follow-up information was collected from the medical 
records. All patients were followed up by measuring their 
PSA levels every 3 months. The median follow-up period 
was 17.9 months (range, 1.0-75.3 months). The endpoint 
of this study was biochemical recurrence. Biochemical re-
currence was defined as detectable PSA levels (greater 
than 0.2 ng/ml on least two occasions), and the time of bio-
chemical recurrence was taken to be the first time PSA be-
came detectable. 
4. Statistical analysis
Pearson correlation coefficients for the relations between 
clinical parameters and total tumor volume were 
generated. Stepwise multivariate linear regression was 
performed to develop a model for predicting tumor volume 
before radical retropubic prostatectomy. The regression 
model in this study included age, body mass index, serum 
PSA, biopsy Gleason score, number of positive biopsy cores, 
and clinical stage. Clinical stage was categorized according 
to organ confinement. Differences in tumor volume (ΔV) 
were calculated by subtracting observed tumor volume 
(V1) from predicted tumor volume (V2). These differences 
were plotted against the mean volume by using the ap-
proach described by Bland and Altman [11]: ΔV=(V2–
V1)x2/(V2＋V1). The receiver operating characteristic 
(ROC) curve was used to indicate the ability of the predicted 
tumor volume to predict several pathologic parameters, 
namely, extracapsular extension, seminal vesicle in-
vasion, and positive surgical margin. For this, areas under 
the ROC curves were estimated. Determining the area un-
der the curve is a suitable way to summarize the overall dis-
criminatory or diagnostic value of a model: the area can 
range from 0.5 (equivalent to flipping a coin, namely, a use-
less model) to 1.0 (perfect discrimination). The more the 
area under the ROC curve approached 100% (i.e., the more 
the ROC curve approached the upper left corner), the great-
er the predictive power. The Kaplan-Meier method was 
used to calculate the biochemical recurrence-free survival 
by predicted tumor volume. The differences were tested 
with the log-rank test. All p-values were two-sided and p
＜0.05 was significant. All statistical analyses were per-
formed with SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) 
programs.
RESULTS  
The patient characteristics are listed in Table 1. Of the 236 
patients, 200 (84.7%) were deemed to have clinically lo-
calized prostate cancer (T1-T2, N0) on the basis of the ini-
tial physical and radiographic evaluation. However, after 
surgery, extracapsular extension was detected in 74 
(31.4%), seminal vesicle involvement was observed in 26 
(11.0%), and 75 (31.8%) had positive surgical margins. 
Correlation coefficients between the tumor volume that 
was determined after radical prostatectomy and various 
clinical parameters were obtained. The correlations be-
tween observed tumor volume and body mass index or biop-
sy Gleason score were low (0.153 and 0.283, respectively). 
The number of positive biopsy cores correlated more 
strongly with observed tumor volume (r=0.489, p＜0.001). 
The highest correlation (r=0.677, p＜0.001) was found be-
tween serum PSA and observed tumor volume (Table 2). 
Moreover, when the patients were divided into two groups 
on the basis of clinical stage, the two groups differed sig-Korean J Urol 2011;52:24-30
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TABLE 1. Patient characteristics
No. (%) Mean±SE Median (range)
Age (yr)
Body mass index 
(kg/cm
2)
Serum PSA (ng/ml)
Biopsy Gleason score
≤6
7
≥8
No. of positive biopsy 
cores
Clinical stage
＜cT3a
≥cT3a
Surgical Gleason score
≤6
7
≥8
Surgical margin
Negative
Positive
Extracapsular 
extension
Negative
Positive
Seminal vesicle 
invasion
Negative
Positive
Observed tumor 
volume (ml)
106 (44.9)
  73 (30.9)
  57 (24.1)
200 (84.7)
  36 (15.3)
  67 (28.3)
133 (56.4)
  36 (15.2)
161 (68.2)
  75 (31.8)
162 (68.6)
  74 (31.4)
210 (89.0)
  26 (11.0)
66.3±0.4
23.8±0.2
12.3±0.9
  3.8±0.2
  7.2±0.6
67.2 (41.8-80.7)
23.9 (15.3-31.1)
8.1 (0.7-98.0)
3.0 (1.0-12.0)
3.7 (0.3-59.9)
SE: standard error, PSA: prostate-specific antigen
TABLE 2. Correlation between clinical parameters and observed
tumor volume
rp - v a l u e
Age (yr) −0.28 0.671
Body mass index (kg/cm
2) 0.153 0.019
Serum PSA (ng/ml) 0.677 ＜0.001
Biopsy Gleason score 0.283 ＜0.001
No. of positive biopsy cores 0.489 ＜0.001
PSA: prostate-specific antigen
FIG. 1. (A) Regression analysis showing the correlation between observed tumor volume and predicted tumor volume (r=0.722, p
＜0.001), for which predicted tumor volume was calculated by using the following equation: [Predicted tumor volume]= 
0.381x[prostate-specific antigen]＋0.921x[No. of positive biopsy cores]−0.992. (B) Bland-Altman analysis of the agreement between
observed tumor volume and predicted tumor volume. The linear line indicates the mean difference. Dotted lines represent 95% 
confidence intervals from the mean of the two volumes. 
nificantly in terms of observed tumor volume (6.4±0.6 for 
patients with ＜cT3a vs. 11.3±1.9 for those with ≥cT3a, 
p=0.020).
The relation between these clinical parameters and ob-
served tumor volume was explored by multiple linear re-
gression analysis. By using the stepwise method described 
earlier, all explanatory variables were eliminated except 
for PSA and the number of positive biopsy cores. This re-
sulted in the equation: [Predicted tumor volume]=0.381x 
[PSA]＋0.921x[No. of positive biopsy cores]−0.992. There 
was a strong correlation between predicted tumor volume 
and observed tumor volume (r=0.722, p＜0.001) (Fig. 1A). 
The mean difference in volume measurements was 0.3 ml 
(range, −1.4-1.7 ml; 95% confidence interval: −0.9-1.5 ml) 
(Fig. 1B).
Fig. 2 presents the areas under the ROC curves, which 
indicate the ability of predicted tumor volume to predict 
pathologic stage. The areas under the ROC curves of pre-
dicted tumor volume were 68.5% for extracapsular ex-
tension, 75.7% for seminal vesicle invasion, and 70.4% for 
positive surgical margin. Thus, overall, predicted tumor 
volume predicted the pathologic results reasonably well. Korean J Urol 2011;52:24-30
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FIG. 2. Ability of predicted tumor volume to predict pathologic outcomes. (A) Extracapsular extension. (B) Seminal vesicle invasion.
(C) Positive surgical margin. 
FIG. 3. Biochemical recurrence-free survivals of patients accor-
ding to median predicted tumor volume (p＜0.001; log-rank 
test). 
The sensitivity and specificity with which various pre-
dicted tumor volume levels predicted pathologic stage are 
also shown in Fig. 2. 
Fig. 3 shows the Kaplan-Meier curves of patients catego-
rized according to predicted tumor volume. The curves re-
vealed that predicted tumor volume correlated sig-
nificantly with biochemical recurrence-free survival (p
＜0.001; log-rank test) when the patients were stratified 
into two groups according to the median value (i.e., less 
than 5 ml or 5 ml or greater).
To validate the above formula, the data for another co-
hort of patients who underwent radical retropubic prosta-
tectomy (n=284), this time between 2005 and 2006, were 
obtained and reviewed. Of these patients, data for 159 were 
available. There was a significant correlation between the 
predicted tumor volume calculated by using the above for-Korean J Urol 2011;52:24-30
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FIG. 4. Observed and predicted tumor volumes of a second cohort of patients who underwent radical retropubic prostatectomy between
2005 and 2006. (A) Regression analysis of all 159 patients (r=0.638, p＜0.001). (B) Bland-Altman analysis of all 159 patients. (C) 
Regression analysis of the 66 patients whose observed tumor volume was ＜3 ml (r=0.277, p=0.024). (D) Bland-Altman analysis of the
66 patients whose observed tumor volume was ＜3 ml.
mula and the observed tumor volume (r=0.638, p＜0.001) 
(Fig. 4A). The mean differences in volume measurements 
amounted to 0.3 ml (range, −1.3-2.0 ml; 95% confidence in-
terval: −0.9-1.6 ml) (Fig. 4B). 
The patients in our series are not representative of most 
patients seen today in North America and Western Europe, 
where 75% of those who receive a diagnosis of prostate can-
cer have nonpalpable disease and tumor volumes that are 
smaller than those observed in our series. Consequently, 
we performed subgroup analysis by using 66 of the 159 pa-
tients whose observed tumor volume was ＜3 ml. There was 
a weak correlation between predicted tumor volume and 
observed tumor volume (r=0.277, p=0.024) (Fig. 4C). The 
mean difference in volume measurements was 0.9 ml 
(range, −0.5-2.0 ml; 95% confidence interval: 0.9-1.8 ml) 
(Fig. 4D).
DISCUSSION
The size of a tumor is an important reflection of its biology, 
which is why tumor size has been reported to correlate di-
rectly with disease extent and to be an important prog-
nostic indicator for prostate cancer. For example, Bostwick 
et al found that progression from capsular invasion to semi-
nal vesicle invasion and finally metastasis was linked to 
increasing tumor volume [5]. Others have also noted that 
small-volume tumors rarely progress, whereas large-vol-
ume tumors progress more frequently [3,12,13]. 
However, a method for accurately estimating the tumor 
volume of prostate cancer before radical prostatectomy is 
still lacking. Although serum PSA correlates with cancer 
volume, its ability to predict tumor size on its own is poor 
[14]. Radiologic imaging techniques often underestimate 
the tumor volume or even fail to detect the tumor [15]. 
Although histologic grade has been shown to correlate with 
actual tumor volume [16], we found that the Gleason score 
derived from preoperative biopsies correlated poorly with 
the actual tumor volume. Furthermore, the needle biop-
sy-based Gleason score was not an independent ex-
planatory variable for tumor volume in this study. 
Because the total tumor volume in the radical prostatec-
tomy specimen correlates with disease extent and may help Korean J Urol 2011;52:24-30
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to predict tumor aggressiveness, we asked whether pre-
operative parameters could serve collectively to predict 
preoperative tumor volume. Two variables, namely, serum 
PSA and the number of positive needle biopsy cores, were 
found to be most highly predictive of observed tumor 
volume. These observations are similar to those made in 
other studies that investigated the predictive power of tu-
mor extent on needle biopsies. For example, Ogawa et al 
found that the number of cancer-positive biopsy cores and 
serum PSA were independently predictive of organ-con-
fined disease [17]. Moreover, Egawa et al reported that the 
number of cores with cancer is jointly predictive of ex-
traprostatic extension in a model that incorporates PSA, 
clinical stage, and Gleason score [18]. In addition, Wills et 
al showed that Gleason score and the number of cancer-pos-
itive cores were the two best predictors of pathologic stage 
[19]. Recently, Ochiai et al found that the number of pos-
itive cores obtained during extended biopsy may be a tool 
for predicting the biological significance of prostate cancer 
[20].
Although actual tumor volume helps to predict tumor ag-
gressiveness, its calculation is time consuming and re-
quires much effort. There are several different ways of esti-
mating the size of tumors in radical prostatectomy speci-
mens, but these methods are not suitable for routine clin-
ical practice. Therefore, an alternative method of estimat-
ing tumor size is desirable. When we established a re-
gression model in which tumor volume was the dependent 
variable and the predicted tumor volume was the ex-
planatory variable, the regression coefficient was sig-
nificant at the 5% level with an adjusted R2=0.521. We also 
found that predicted tumor volume was a reasonable pre-
dictor of pathologic stage. 
This study suffered from several limitations. First, be-
cause this study was conducted retrospectively, it may suf-
fer from the typical biases of such research, including re-
ferral, selection, and inclusion biases. Second, at the time 
of analysis, the median follow-up period of the cohort was 
only 17.9 months, which hampered our ability to analyze 
the associations of predicted tumor volume with pro-
gression variables. Third, the percentage of needle biopsy 
core length that involved tumor was not reported con-
sistently in our series, which meant that we could not ana-
lyze the relationship between this variable and predicted 
tumor volume. It may be that the percentage of cores with 
adenocarcinoma is useful for predicting the outcomes of 
pathologic or biochemical recurrence. However, this limi-
tation may be less serious because the number of positive 
cores may indicate tumor extent in needle biopsy speci-
mens more quantitatively and reproducibly than visual in-
spection estimates of the percentages of prostate needle bi-
opsy tissue that contains carcinoma [21]. Furthermore, the 
prostate gland was typically sampled by 12-core biopsies 
in the present study. Increased sampling may improve the 
ability of tumor extent in needle biopsy specimens to accu-
rately reflect whole-gland tumor volume [22]. 
CONCLUSIONS
The prediction of pathologic stage is a key element in pros-
tate cancer treatment decision-making. We found that tu-
mor volume predicted on the basis of PSA levels and the 
number of positive biopsy cores predicted pathologic stage 
with reasonable accuracy. Thus, this method of pre-
operatively predicting tumor volume may improve the de-
cision-making regarding patients with prostate cancer.
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